Oncology and Hematology

Episodes 49-64 of 116

• 

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  MinuteCE®

  Integrating Bispecific Antibodies Into Clinical Practice

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  RestartResume

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  MinuteCE®

  The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  RestartResume

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  MinuteCE®

  Preventing CRS and Neurotoxicities Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  RestartResume

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  MinuteCE®

  Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  RestartResume

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  MinuteCE®

  Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  RestartResume

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  MinuteCE®

  First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  1.00 program credit

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  MinuteCE®

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  RestartResume

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  MinuteCE®

  Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  RestartResume

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  MinuteCE®

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC

  RestartResume

  The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC

  MinuteCE®

  The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  MinuteCE®

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  MinuteCE®

  Next-Generation TKI Therapy for ROS1-Rearranged NSCLC

  1.00 credit 9 episodes

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 credit 9 episodes

• 

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  MinuteCE®

  Efficacy Data for Bispecific Antibodies in RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Considerations for Dosing Bispecific Antibodies

  RestartResume

  Considerations for Dosing Bispecific Antibodies

  MinuteCE®

  Considerations for Dosing Bispecific Antibodies

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  MinuteCE®

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  Intracranial Activity of ROS1 TKIs

  RestartResume

  Intracranial Activity of ROS1 TKIs

  MinuteCE®

  Intracranial Activity of ROS1 TKIs

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit